$266.31
+ 1.81+ 0.68%
CacheUpdated 19:01May Be Out Of Date
No data
This data isn't available right now.
No data
No data
Industry: Biotechnology
Couldn't load data
Average close over the last 50, 100 and 200 trading days. The percentage next to it is how far the current price sits from that average.
Balance-sheet ratios aren't available for this company.
It is an automated pre-screen based on the line of business and AAOIFI's widely used financial thresholds; a final judgement rests with your own school of thought and the certification boards that audit the filings.
The interest-income test (5% of revenue) needs a revenue breakdown our free data source doesn't provide, so that criterion isn't screened.
Alnylam pioneered RNA interference therapy, silencing faulty proteins at the genetic source before they are made.
CacheUpdated 13:02May Be Out Of Date